MAPT and Alzheimer disease: IWG criteria consider β‐amyloid and tau to be of ‘low predictive accuracy’ for the development of cognitive symptoms and classify such individuals as ‘at risk for progression to AD’, contrary to the more pessimistic designation of ‘preclinical AD’ as recommended by NIA‐AA.